The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; none of the 11 sources its claims cite is checked for support yet.
B cells and tertiary lymphoid structures promote immunotherapy response
Open accessAbstract
Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers 1-10 and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity 11-15, although these have been less well-studied in ICB treatment 16. A previously conducted neoadjuvant ICB trial in patients with melanoma showed via targeted expression profiling 17 that B cell signatures were enriched in the tumours of patients who respond to treatment versus non-responding patients. To build on this, here we performed bulk RNA sequencing and found that B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders. Our findings were corroborated using a computational method (MCP-counter 18) to estimate the immune and stromal composition in this and two other ICB-treated cohorts (patients with melanoma and renal cell carcinoma). Histological evaluation highlighted the localization of B cells within tertiary lymphoid structures. We assessed the potential functional contributions of B cells via bulk and single-cell RNA sequencing, which demonstrate clonal expansion and unique functional states of B cells in responders. Mass cytometry showed that switched memory B cells were enriched in the tumours of responders. Together, these data provide insights into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
48 Own result · 19 Own method · 11 Own interpretation · 9 Not checked yet
None of the sources cited for this claim have been checked yet.
In the paper
“Moreover, these findings were corroborated in translational studies of separate cohorts of patients with melanoma36 and sarcoma37 who were treated with ICB.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
What the sources say
- Not checked yetcites [36] Cabrita, R. L. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature https://doi.org/10.1038/s41586-019-1914-8 (2020). source
- Not checked yetcites [37] Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature https://doi.org/10.1038/s41586-019-1906-8 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“B cells were not significantly associated with pathological response rates in an analogous trial of neoadjuvant-targeted therapy in patients with BRAF-mutated melanoma38”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
What the sources say
- Not checked yetcites [38] Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181–193 (2018). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Findings of high B cell lineage scores in responders were replicated in samples from an additional cohort of patients with melanoma treated with neoadjuvant versus adjuvant checkpoint blockade (ClinicalTrials.gov identifier NCT02437279, OpACIN-neo trial) (n = 12 responders, 6 non-responders)35”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
What the sources say
- Not checked yetcites [35] Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018). source
plaincorrelationaln = 12- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“B cell signatures alone were predictive of response in univariable analyses (odds ratio 2.6, P = 0.02 for our trial, and odds ratio 2.9, P = 0.03 for combined melanoma cohorts)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but not in multivariable analyses when considering other components of the immune cell infiltrate”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In these analyses, we again observed enrichment of a B cell signature in responders versus non-responders at baseline and early on-treatment (P = 0.036 and 0.038, respectively).”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gene expression profiling by microarray and subsequent MCP-counter analysis of baseline tumour samples was performed, demonstrating significantly higher expression of B-cell-related genes in responders versus non-responders (P = 0.0011, n = 17 responders and 11 non-responders)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Similar B cell signature observed in RCC
boostedcorrelationaln = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other genes that are expected to alter the function of B cells were also significantly enriched in responders versus non-responders, such as FCRL5, IDO1, IFNG and BTLA.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“here we performed bulk RNA sequencing and found that B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“TLSs are associated with markers of T cell activation and response and B cell proliferation.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 28
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“significantly higher expression of B-cell-related genes such as MZB1, JCHAIN and IGLL5 was observed in patients that respond to ICB treatment versus non-responding patients (‘responders’ and ‘non-responders’, hereafter) at baseline (P < 0.001) with over-representation of these genes compared to T cells and other immune markers (with evaluable tumours from seven responders and nine non-responders)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Importantly, there was no clear association of MICs with known genomic subtypes of melanoma (BRAF, NRAS, NF1 or triple wild type)42 or disease site (nodal or non-nodal)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells prognostic in TCGA analysis
What the sources say
- Not checked yetcites [42] Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015). source
plainn = 136- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pathway analysis was also performed on bulk RNA-seq data from our clinical trial cohort, revealing increased immune signalling pathways in responders than in non-responders, including T cell receptor signalling, major histocompatibility complex-mediated antigen presentation and processing, differentiation of T helper 1 and 2 (TH1 and TH2) cells, and costimulatory signalling associated with T cell”
§ B cells and tertiary lymphoid structures promote immunotherapy response > BCR and single-cell RNA-seq offer functional insight
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For tumour, this included 9 responders and 9 non-responders, and for peripheral blood mononuclear cells, 8 responders and 8 non-responders.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Sample preparation and acquisition
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Similar analyses were performed to assess the expression of immune-related genes in clear-cell RCC from the TCGA (TCGA-KIRC, n = 526)43. In these analyses, similar immune classes were observed; however, immune infiltration was not associated with survival in these patients (P = 0.24)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells prognostic in TCGA analysis
What the sources say
- Not checked yetcites [43] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013). source
plainn = 526- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“yielding a final stage III TCGA-SKCM cohort of n = 136.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > TCGA SKCM and KIRC data downloading and patient selection
plainn = 136- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“resulting in a median of approximately 1.4 million paired-end reads and a median of 2,588 genes detected per cell.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Single-cell sequencing and analysis of CD45+ B cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The density of CD20+ B cells and TLSs, and the ratio of TLSs to tumour area were higher in responders than in non-responders in our neoadjuvant melanoma cohort, particularly in early on-treatment samples (P = 0.0008, P = 0.001 and P = 0.002, respectively), although statistical significance was not reached for all the markers in the baseline samples (P = 0.132, P = 0.078 and P = 0.037, respectively”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells localized in the context of TLSs
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we identified significantly increased clonal counts for both immunoglobulin heavy and light chains (IgH and IgL; P = 0.001 and P = 0.004, respectively) and increased BCR diversity in responders than in non-responders (P = 0.002 and P = 0.0008)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > BCR and single-cell RNA-seq offer functional insight
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other notable differences included an increase in plasma cells in responders compared with non-responders; however, this did not reach significance and was largely driven by data from one patient (P = 0.3)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > CyTOF shows differential B cell phenotypes
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For TCGA-KIRC, the cases without available expression data were excluded and a total of 526 cases were taken into subsequent analysis.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > TCGA SKCM and KIRC data downloading and patient selection
plainn = 526- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant differences were identified when testing for associations of each individual cluster (G1–G4) with the clinical outcome, probably owing to limited sample size.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > BCR and single-cell RNA-seq offer functional insight
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analogous immunohistochemical findings were observed in our cohort of patients with RCC treated with pre-surgical ICB, with increased infiltration of CD20+ cells and TLSs density associated with response to treatment (Extended Data Fig. 6b–d); these TLSs are morphologically similar to those found in melanoma”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells localized in the context of TLSs
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“TLSs are associated with response in RCC similar to those observed in melanoma.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
plaincorrelationaln = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“tumours from responders had a significantly higher frequency of memory B cells, whereas non-responders had a significantly higher frequency of naive B cells (P = 0.033 for naive and P = 0.033 for memory)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > CyTOF shows differential B cell phenotypes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the case of melanoma, B cell signatures were predictive of a response in univariable analysis in the RCC cohort (odds ratio 61.2, P = 0.05) but not multivariable analysis”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Similar B cell signature observed in RCC
plaincorrelationaln = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Survival data were missing for 9 of 136 samples, so n = 127 samples were available for overall survival analyses.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > TCGA SKCM and KIRC data downloading and patient selection
plainn = 127- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“we found that B cells were significantly enriched in tumours from responders versus non-responders and were predictive of a response (odds ratio 1.05, P = 0.02)”
§ B cells and tertiary lymphoid structures promote immunotherapy response > BCR and single-cell RNA-seq offer functional insight
What the sources say
- Not checked yetcites [44] Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018). source
plaincorrelationaln = 48- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This process yielded a median robustness measure of 0.96 for the selected k=11.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Unsupervised clustering of immune cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are 28 available pre-treatment samples from 3 arms: nivolumab (n = 6), nivolumab plus bevacizumab (n = 14) and nivolumab plus ipilimumab (n = 8).”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Affymetrix microarray for RCC
plainn = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“architectural analysis showed that CD20+ B cells were localized in TLSs of tumours of responders, and were colocalized with CD4+, CD8+and FOXP3+ T cells.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells localized in the context of TLSs
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which suggests that B cells probably act together with other immune subsets and are not acting in isolation”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“however, B cells have previously been shown to be positively associated with responses to chemotherapy in other cancer types39,40.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells found in the tumours of responders
What the sources say
- Not checked yetcites [39] Reddy, S. M. et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. Cancer Immunol. Res. 7, 1025–1035 (2019). source
- Not checked yetcites [40] Song, I. H. et al. Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res. Treat. 49, 399–407 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“however, sample size was again limited”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Similar B cell signature observed in RCC
plainn = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No statistical methods were used to predetermine sample size.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The correlation matrix was carefully reviewed and the sequencing event generated from one library pool that showed poor correlation with other library pools from the same RNA sample were removed before sample-level merging of BAM files.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > RNA-seq data processing and quality check
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Samples with fewer than 200 CD45+CD19+ B cells were not used for downstream analyses.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Data analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observation of switched memory B cells (that can differentiate into plasma cells) in responders suggests that they could be potentially contributing to the anti-tumour response by producing antibodies against the tumours.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Summary
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: Switched memory B cells can differentiate into plasma cells.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Representative transmission electron micrographs showing Dynabead with exosomes present after immunocapture.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“for each patient, we collected and sequenced the same number of cells (n = 384 CD45+ cells per plate). Thus, the number of cells per patient is equal”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Single-cell sequencing and analysis of CD45+ B cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“RNA quality was assessed on an Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano Chip with smear analysis to determine DV200 and original RNA concentration.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Gene expression profiling and analysis: RNA extraction for neoadjuvant melanoma ICB-treated cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Technical replicates were constrained to n = 1 per time point, owing to limited tissue availability in patient-derived samples as well as prioritization for multiple studies.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Nanoimager-captured images of the beads coated with CD63+ exosomes as compared with isotype control.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Protein targets with a signal to noise ratio less than 2 were removed from downstream analysis.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > nCounter hybridization assay for photocleaved oligo counting
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Five random areas on each sample were analysed blindly by a pathologist at 20× magnification.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Multiplex immunofluorescence assay and analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Only in-frame productive clonotypes were taken into subsequent analysis.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > B cell clonotype analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These data represent combined tumour and peripheral blood samples from patients with melanoma treated with ICB ran together (8 tumour n = 5 R and n = 3 NR and 8 peripheral blood samples n = 4 R and n = 4 NR), thus eliminating batch effect.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
plaindirectn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The experiments were not randomized”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For one sample, the Nanosight measurement was erroneous and excluded. All samples were included in the flow cytometric analyses.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Flow cytometric analyses of exosomes
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The reads that had ≥ 15 contiguous low-quality bases (phred score < 20) were removed from the FASTQ files.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > RNA-seq data processing and quality check
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“investigators were not blinded to allocation during experiments and outcome assessment unless stated otherwise.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Statistical analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identify similar mature TLSs in patients with extra-nodal metastases (Extended Data Fig. 5b), which suggests that TLSs may develop in non-nodal sites and are associated with the response to ICB treatment.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > B cells localized in the context of TLSs
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Responder versus non-responder status was blinded until flow cytometry data capture and FlowJo analyses were completed.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Methods > Flow cytometric analyses of exosomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
B cells can secrete cytokines including TNF, IL-2, IL-6, and IFNγ, and through these cytokines activate and recruit other immune effector cells including T cells.
“B cells can also secrete an array of cytokines (including TNF, IL-2, IL-6 and IFNγ), through which they activate and recruit other immune effector cells, including T cells.”
The paper relies on this without support.
Switched memory B cells can differentiate into plasma cells.
“switched memory B cells (that can differentiate into plasma cells)”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, as a member of the 12-chemokine gene signature classifier33, its expression has been correlated with the presence of tumor-associated tertiary lymphoid structures50–52 which are rapidly emerging as a powerful prognostic marker in melanoma and a number of other cancer types53–55.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [54]
Experimental — accuracy not yet measuredIn the citing paper
“Tertiary lymphoid structures (TLS) have recently emerged as biomarkers of response to ICT across several tumor types, including lung cancer, melanoma, RCC, sarcoma, and urothelial cancer (163-167).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [164]
In the citing paper
“Presence of B cells in tumor was associated with a better response to neoadjuvant therapy with ICB in melanoma and renal cell carcinoma (Cabrita et al., 2020; Helmink et al., 2020).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Helmink et al., 2020
In the citing paper
“Tumor-infiltrating B cell populations in responder tumors were enriched in memory B cells; in contrast, naïve B cells were more prominent in non-responder tumors (Helmink et al., 2020).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Helmink et al., 2020
In the citing paper
“Mounting evidence on the role of the gut and tumor microbiome, stress, and diet in tumor immunity and response to ICB (Helmink et al., 2020) has created a foundation for emerging adjunct therapies.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Helmink et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
“Figure: Extended Data Fig. 4 | Immune infiltrate is prognostic of improved diseasespecific survival in TCGA cutaneous melanoma cohort but not the clear-cell RCC cohort.”
§ B cells and tertiary lymphoid structures promote immunotherapy response > Extended Data
“b, Kaplan–Meier estimates of overall survival of MIC groups. c, Kaplan–Meier estimates of overall survival by B cell lineage scores shown by high and low groups dichotomized by median values.”
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888 · cited 1×
“In the bulk-tissue, the differentially expressed genes which had a q-value <0.05 and log2foldchange >1.5 were & -1.5 were selected as input for network based pathway enrichment analysis using ReactomeFiViz 47 application in Cytoscape 48,49 .”
InfluentialSTAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“5.3) 40 was then performed on the filtered FASTQ files with default parameters to generate RNA-seq BAM file for each sequencing event.”
Influentiallimma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“The Limma R software package 44 was used to identify DEGs from normalized microarray data for the RCC cohort.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 2×
“Significant progress has been made in this regard, with the identification of several validated biomarkers, particularly for immune checkpoint blockade (ICB) 1-10 .”
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationCytoscape 2.8: new features for data integration and network visualization
Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P., & Ideker, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq675 · Cited by 4,770
Controlling the false discovery rate in behavior genetics research
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00297-2 · Cited by 4,146
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Cited by
Sorted by citations
Items 401–500 of 1,004
Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling
Johansson, A., & Ganß, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674375 · Cited by 65
“Furthermore, RNA-seq analysis of B cell receptors (BCRs) in melanomas showed greater BCR diversity and B cell maturity in ICB responders versus non-responders supporting an active role for B cells in anti-tumor immunity (71).”
BackgroundCho, J.-W., Park, S., Kim, G., Han, H., Shin, S., Shin, S., Bae, Y., Park, S. Y., Ha, S., Lee, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26362-0 · Cited by 66
Gao, S., Liu, S., Wang, G., & Zhou, G. (2021) · Life · doi:10.3390/life11121282 · Cited by 69
“An increased interest in developing a responsive biomarker and target for immune checkpoint therapy has focused on the role of B cells and the TLS, which are associated with favorable outcomes for patients after immunotherapy [51,141,195,197].”
BackgroundIgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer
Mandal, G., Biswas, S., Anadon, C. M., Yu, X., Gatenbee, C., Prabhakaran, S., Payne, K. K., Chaurio, R. A., Martin, A., Innamarato, P., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2376 · Cited by 66
Wang, Q., Shen, X., An, R., Bai, J., Dong, J., Cai, H., Zhu, H., Zhong, W., Chen, W., Liu, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962056 · Cited by 65
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 73
“However, it has become increasingly clear that the presence of Tfh cells (159-161) and B cells (162-170) is correlated with prolonged survival, as well as positive therapeutic responsiveness in patients with a wide variety of cancers (164,165,168).”
BackgroundEmerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 62
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
Sánchez‐Alonso, S., Setti-Jerez, G., Arroyo, M., Hernández, T., Martos, M. I., Sánchez-Torres, J. M., Colomer, R., Ramiro, A. R., & Alfranca, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001187 · Cited by 66
CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 66
Antoranz, A., Herck, Y. V., Bolognesi, M. M., Lynch, S. M., Rahman, A., Gallagher, W. M., Boecxstaens, V., Marine, J., Cattoretti, G., van den Oord, J. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0363 · Cited by 63
“10, 11), specific cytotoxic T cell (Tcy) subtypes such as progenitor-exhausted Tcy (12), tumor-infiltrating B cells and tertiary lymphoid structures (13, 14), intratumoral and gut microbiota (15, 16), myeloid-derived suppressor cells (17), cancer-associated fibroblasts (18), and tumor-associated high-endothelial venul…”
BackgroundActivation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Fridman, W. H., Sibéril, S., Pupier, G., Soussan, S., & Sautès‐Fridman, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101703 · Cited by 67
Self-citationZhang, N., Qu, F., Liu, H., Li, Z., Zhang, Y., Han, X., Zhu, Z., & Lv, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02242-x · Cited by 63
CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response
Wu, Z., Zhou, J., Xiao, Y., Ming, J., Zhou, J., Dong, F., Zhou, X., Xu, Z., Zhao, X., Lei, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865596 · Cited by 65
“IgA plasmocytes within prostate tumors were reported to diminish tumoral CTL activation through TGFb receptor signaling (4, 12, 49).”
BackgroundMethodResultInfluentialVats, K., Kruglov, O., Sahoo, B., Soman, V., Zhang, J., Shurin, G. V., Chandran, U. R., Skums, P., Shurin, M. R., Zelikovsky, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0110 · Cited by 63
Enablers and challenges of spatial omics, a melting pot of technologies
Alexandrov, T., Sáez-Rodríguez, J., & Saka, S. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202110571 · Cited by 65
“Moreover, spatial omics already helped pinpointing specific tissue architecture, cell composition, and functional states of cells associated with the therapy response (Zhao et al , 2019; Helmink et al , 2020).”
Han, P.-Z., Ye, W.-D., Yu, P., Tan, L.-C., Xiao Hua, S. H. I., Chen, X.-F., He, C., Hu, J., Wei, W., Lu, Z., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173712 · Cited by 69
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 64
Self-citationCarril-Ajuria, L., Desnoyer, A., Meylan, M., Dalban, C., Naigeon, M., Cassard, L., Vano, Y. A., Rioux-Leclercq, N. C., Chouaı̈b, S., Beuselinck, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004885 · Cited by 63
“17 22–25 Specifically, in the study conducted by Helmink and colleagues, tumors from responder patients were enriched in memory B cells and presented increased plasma cells compared with tumors from non-responders.”
InfluentialSelf-citationSenescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword
Battram, A. M., Bachiller, M., & Martín-Antonio, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124346 · Cited by 66
Ko, A. H., Jordan, A. C., Tooker, E., Lacey, S. F., Chang, R. B., Li, Y., Venook, A. P., Tempero, M. A., Damon, L. E., Fong, L. H., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.017 · Cited by 63
Emerging principles of brain immunology and immune checkpoint blockade in brain metastases
Fares, J., Ulasov, I. V., Timashev, P. S., & Lesniak, M. S. (2021) · Brain · doi:10.1093/brain/awab012 · Cited by 63
Bertucci, F., Boudin, L., Finetti, P., Berckelaer, C. V., van Dam, P. A., Dirix, L. Y., Viens, P., Gonçalvès, A., Ueno, N. T., Laere, S. V., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929724 · Cited by 60
Li, C., Wu, J., Jiang, L., Zhang, L., Huang, J., Tian, Y., Zhao, Y., Liu, X., Xia, L., Haoran, E., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03262-w · Cited by 62
Hu, B., Sajid, M., Lv, R., Liu, L., & Sun, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996721 · Cited by 60
Palomero, J., Panisello, C., Lozano-Rabella, M., Tirtakasuma, R., Díaz-Gómez, J., Grases, D., Pasamar, H., Arregui, L., Duch, E. D., Guerra, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005443 · Cited by 65
Defining and using immune archetypes to classify and treat cancer
Combes, A. J., Samad, B., & Krummel, M. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00578-2 · Cited by 61
“…TMEs are dominated by a T reg cell–exhausted T cell suppressing axis 45 , but only the TC-Mac archetype expresses CXCL13 — a mark of TLS formation 67 and extrafollicular response, which might provide essential CD4 help (through CD40–CD40L engagement) to CD8 + tumour-specific T cells 157 (Fig.”
BackgroundVries, N. L. D., Mahfouz, A. E., Koning, F., & de Miranda, N. F. C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01254 · Cited by 58
Tang, J., Ramis‐Cabrer, D., Curull, V., Wang, X., Mateu-Jiménez, M., Pijuán, L., Durán, X., Qin, L., Rodríguez-Fuster, A., Aguiló, R., et al. (2020) · Cancers · doi:10.3390/cancers12092644 · Cited by 61
“These are relevant findings that are line with recent reports [26,29,30], in which B cell-enriched TLSs were the best prognostic factor among study patients regardless of the proportions of T cells.”
BackgroundResultInfluentialOpportunities for Nitric Oxide in Potentiating Cancer Immunotherapy
Kim, J., & Thomas, S. N. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000500 · Cited by 60
“, 1988), which in turn modulate T cell priming and response to immune checkpoint blockade therapy (Candolfi et al., 2011; Wang et al., 2016; Griss et al., 2019; Cabrita et al., 2020; Helmink et al., 2020; Petitprez et al., 2020).”
BackgroundHolzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 67
“All cell lines were used at low passage, 70% con fl uency, and were cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, MilliporeSigma) and 1% (v/v) penicillin/streptomycin (Life Technologies) as described 33,34,57 .”
Dixon, M. L., Luo, L., Ghosh, S., Grimes, J. M., Leavenworth, J. D., & Leavenworth, J. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01450-3 · Cited by 57
“The enhanced responsiveness to antiPD-1 treatment may also result from the increased TIL TFH/GC B-cell responses, as reported by recent clinical studies [15, 16], despite no success in detecting the TLS formation in our mouse models.”
ResultQiu, M.-Z., Wang, C., Wu, Z., Zhao, Q., Zhao, Z., Huang, C.-Y., Wu, W., Yang, L.-Q., Zhou, Z.-W., Zheng, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01622-1 · Cited by 58
“24,25 Indeed, the tumours of EBV ( + ) GC patients exhibited signi fi cant enrichment of both B-cell signatures and germinal centre signatures (Fig.”
BackgroundHosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine development
Tabachnick‐Cherny, S., Pulliam, T., Church, C. D., Koelle, D. M., & Nghiem, P. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23190 · Cited by 69
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 59
“Antigen-presenting cells can infiltrate tumors and present antigens to lymphocytes in the tumor microenvironment (7, 8) or in tumor-draining lymph nodes.”
BackgroundSelf-citationAppleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Ono, M., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 63
“Indeed, a study of ICPI therapy in melanoma showed enrichment of B cell signatures in responding patients (164), and conditional knockout of novel checkpoint TIM-3 on DCs was shown to lead to inflammasome activation and antitumour immunity, an effect that was not seen with TIM-3 deletion on CD4 or CD8 Tcells (165).”
BackgroundWhen breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
van Vugt, M. A. T. M., & Parkes, E. E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.003 · Cited by 59
Prognostic significance of spatial immune profiles in human solid cancers
Tsujikawa, T., Mitsuda, J., Ogi, H., Miyagawa‐Hayashino, A., Konishi, E., Itoh, K., & Hirano, S. (2020) · Cancer Science · doi:10.1111/cas.14591 · Cited by 58
Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications
Yshii, L., Bost, C., & Liblau, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00991 · Cited by 62
Blise, K. E., Sivagnanam, S., Banik, G. L., Coussens, L. M., & Goecks, J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00253-z · Cited by 58
Wang, B., Liu, J., Yin, H., Deng, Y., Li, J., & Jiang, Y. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868155 · Cited by 58
“TLSs not only are prognostic biomarkers of improved clinical outcome among cancer patients but also shape a local and favorable site for generating antitumor humoral and cellular immune responses (6, 8).”
BackgroundResultImmunotherapy approaches for malignant pleural mesothelioma
Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 62
Li, T., Li, Y., Zhu, X., He, Y., Wu, Y., Ying, T., & Xie, Z. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.007 · Cited by 60
Jin, X., Liang, J., Zhang, S., Ji, P., Huang, Q., Qin, Y., Deng, X., Liu, C., & Zhang, X. (2023) · Materials Horizons · doi:10.1039/d3mh00748k · Cited by 58
Self-citationChen, Z., Wang, X., Jin, Z., Li, B., Jiang, D., Wang, Y., Jiang, M., Zhang, D., Yuan, P., Zhao, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00579-w · Cited by 65
“Tertiary lymphoid structures (TLSs) are organized aggregation of immune cells resembling secondary lymphoid organs 1 – 3 .”
B cell immunometabolism in health and disease
Martinis, E., Tonon, S., Colamatteo, A., Cava, A. L., Matarese, G., & Pucillo, C. E. M. (2025) · Nature Immunology · doi:10.1038/s41590-025-02102-0 · Cited by 65
Jing, S., Wang, H.-Q., Lin, P., Yuan, J., Tang, Z., & Li, H. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00857-1 · Cited by 65
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity
Milutinovic, S., Abe, J., Godkin, A. J., Stein, J. V., & Gallimore, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.001 · Cited by 57
Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy
Li, H., Ding, J., Zhang, M.-J., Yu, H., & Sun, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216293 · Cited by 56
Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta
O’Connor, R. A., Martinez, B. R., Koppensteiner, L., Mathieson, L., & Akram, A. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221532 · Cited by 63
Schenk, K. M., Deutsch, J. S., Chandra, S., Davar, D., Eroglu, Z., Khushalani, N. I., Luke, J. J., Ott, P. A., Sosman, J. A., Aggarwal, V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01497 · Cited by 57
“These fi ndings support a growing body of evidence that ICI may exert their down-stream effects by activating B cells, 37-39 and suggest that medications (eg, antithymocyte globulin) or other interventions (eg, plasma exchange) may be bene fi cial among SOTR experiencing ICI-related allograft…”
BackgroundMolecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome
Nayar, S., Turner, J. D., Asam, S., Fennell, É., Pugh, M., Colafrancesco, S., Berardicurti, O., Smith, C. G., Flint, J., Teodòsio, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54686-0 · Cited by 57
Effects of B cell–activating factor on tumor immunity
Yarchoan, M. M., Ho, W. J., Mohan, A. A., Shah, Y., Vithayathil, T., Leatherman, J. M., Dennison, L., Zaidi, N., Ganguly, S., Woolman, S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136417 · Cited by 56
Storkus, W. J., Maurer, D. M., Lin, Y., Ding, F., Bose, A., Lowe, D. B., Rose, A. E., DeMark, M., Karapetyan, L., Taylor, J. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003675 · Cited by 58
Self-citationChen, W., Dong, K., Pan, X., Gan, S., Xu, D., Chen, J.-X., Chen, W., Li, W., Wang, Y., Wang, Z., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05566-w · Cited by 60
“Processed data could be accessed at https://doi.org/10.6084/m9. fi gshare.21625964 after reasonable request.”
InfluentialZhang, P., Wang, Y., Miao, Q., & Chen, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115569 · Cited by 60
Community assessment of methods to deconvolve cellular composition from bulk gene expression
White, B. S., de Reyniès, A., Newman, A. M., Waterfall, J. J., Lamb, A. E., Petitprez, F., Lin, Y., Yu, R., Guerrero-Gimenez, M. E., Domanskyi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50618-0 · Cited by 61
Self-citationRausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 66
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies
Benavente, S., Sánchez-García, A., Naches, S., LLeonart, M. E., & Lorente, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.582884 · Cited by 57
Briviesca, R. L., Cruz‐Bermúdez, A., Nadal, E., Insa, A., García-Campelo, R., Huidobro, G., Dómine, M., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.491 · Cited by 52
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Fucikova, J. P., Coosemans, A., Oršulić, S., Cibula, D., Vergote, I. B., Galluzzi, L., & Špíšek, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002873 · Cited by 55
Koh, J., Kim, S., Woo, Y. D., Song, S. G., Yim, J., Han, B., Lim, S., Ahn, H. K., Mun, S., Kim, J. S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.004 · Cited by 57
Li, Y., Jia, G.-D., Lv, X., Xie, S., Guo, S.-S., Lin, D.-F., Liu, L., Luo, D., Li, Y., Deng, S.-W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40402-x · Cited by 59
Xu, W., Lu, J., Tian, X., Ye, S., Wei, S., Wang, J., Anwaier, A., Qu, Y., Liu, W., Chang, K. S., et al. (2024) · MedComm · doi:10.1002/mco2.461 · Cited by 55
“13,29,40,41 Since the intratumoral TLS that predict the better prognosis are predominantly mature TLS, investigating if TLS maturation could be the confounding reason for the difference in prognostic associations in ccRCC rather than the localization constitutes a possible goal for future research.”
BackgroundSelf-citationNew horizons at the interface of artificial intelligence and translational cancer research
Yates, J., & Allen, E. M. V. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.018 · Cited by 58
Cervical Cancer: Emerging Immune Landscape and Treatment
Guo, L., & Hua, K. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s264312 · Cited by 57
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Kamal, Y., Schmit, S. L., Frost, H. R., & Amos, C. I. (2020) · Immunotherapy · doi:10.2217/imt-2020-0026 · Cited by 56
“Although anti-tumor immune responses are predominately focused on the role of T cells, new evidence from metastatic melanoma and sarcoma suggests B cells may play a greater role than previously thought in fighting disease metastasis [40].”
BackgroundA comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma
Yang, H., Zhao, L., Zhang, Y., & Li, F. (2021) · Cancer Medicine · doi:10.1002/cam4.4117 · Cited by 52
Yang, G., Su, X., Yang, H., Luo, G., Gao, C., Zheng, Y., Xie, W., Huang, M., Bei, T., Bai, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3352 · Cited by 54
“Tertiary lymphoid structures (TLSs), which predicted favorable prognosis and improved response to immunotherapy in several solid tumors, were also observed in the resected tumor of responders, corroborating the favorable responses in these patients (16-18).”
ResultBaretti, M., Danilova, L., Durham, J. N., Betts, C. B., Cope, L., Sidiropoulos, D. N., Tandurella, J. A., Charmsaz, S., Groß, N., Hernandez, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52528-7 · Cited by 59
Grasso, C. S., Tsoi, J., Onyshchenko, M. I., Abril-Rodríguez, G., Ross‐Macdonald, P., Wind‐Rotolo, M., Champhekar, A. S., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.015 · Cited by 55
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
Gibellini, L., Biasi, S. D., Porta, C., Tartaro, D. L., Depenni, R., Pellacani, G., Sabbatini, R., & Cossarizza, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00490 · Cited by 55
LLT1-CD161 Interaction in Cancer: Promises and Challenges
Braud, V. M., Meghraoui, A., Elaldi, R., Petti, L., Germain, C., & Anjuère, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847576 · Cited by 54
“Similarly, B cell and TLS signatures as well as T effector signatures predicted responses to anti-PD-1 and anti-CTLA-4 antibodies in melanomas and renal cell carcinomas (117, 120).”
BackgroundZhang, T., Lei, X., Jia, W., Li, J., Nie, Y., Mao, Z., Wang, Y., Tao, K., & Song, W. (2022) · Cancer Medicine · doi:10.1002/cam4.5227 · Cited by 53
Technology meets TILs: Deciphering T cell function in the -omics era
Hudson, W. H., & Wieland, A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.011 · Cited by 55
Targeting STING in cancer: Challenges and emerging opportunities
Zhao, K., Huang, J., Zhao, Y., Wang, S., Xu, J., & Yin, K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188983 · Cited by 57
An, M., Mehta, A., Min, B., Heo, Y. J., Wright, S. J., Parikh, M., Bi, L., Lee, H., Kim, T. J., Lee, S.-Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0857 · Cited by 58
“33).”
Self-citationPeripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 56
Yin, X., Wang, Z., Wang, J., Xu, Y., Kong, W., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933332 · Cited by 52
Stromal cells in tertiary lymphoid structures: Architects of autoimmunity
Asam, S., Nayar, S., Gardner, D. H., & Barone, F. (2021) · Immunological Reviews · doi:10.1111/imr.12987 · Cited by 52
Wortman, J. C., He, T.-F., Solomon, S. T., Zhang, R. Z., Rosario, A., Wang, R., Tu, T. Y., Schmolze, D. B., Yuan, Y., Yost, S. E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00291-z · Cited by 55
Chen, Z., Huang, Y., Hu, Z., Zhao, M., Bian, Y., Chen, Z., Zheng, Y., Bi, G., Pang, Y., Zhan, C., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00359-2 · Cited by 52
“Given these findings, recent reviews have identified a key role for plasma B cells in oncology and patient outcomes [51, 52].”
BackgroundHe, T., Hao, Z., Lin, M., Xin, Z., Chen, Y., Ouyang, W., Yang, Q., Chen, X., Zhou, H., Zhang, W., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093054 · Cited by 54
“Moreover, B cells in TLSs may contribute to the effective T-cell response after ICB treatment.(36) In”
BackgroundAnagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 52
Han, Z., Zhang, C., An, J., Wang, Y., Qiao, J., Zeng, X., & Zhang, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302728 · Cited by 52
Tumor-derived nanoseeds condition the soil for metastatic organotropism
Hu, M., Kenific, C. M., Boudreau, N. J., & Lyden, D. C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.003 · Cited by 53
Gavrielatou, N., Fortis, E., Spathis, A., Anastasiou, Μ., Economopoulou, P., Foukas, G. R. P., Lelegiannis, I. M., Rusakiewicz, S., Vathiotis, I. A., Aung, T. N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.011 · Cited by 53
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 54
“types, including pancreatic cancer, and are a biomarker for response to immune checkpoint blockade in melanoma.(39,42,43) Additionally, examination of resected pancreatic cancer tissue from patients who were treated with the cancer vaccine GVAX (an irradiated, granulocyte‐macrophage colony‐stimulating factor secreting…”
BackgroundLu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q., Sun, S., Guo, X., Yin, H., Wei, Y., Li, S., et al. (2020) · Hepatology · doi:10.1002/hep.31502 · Cited by 52
B Cell Response to Vaccination
Luo, W., & Yin, Q. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1903033 · Cited by 55
“Interestingly, recent findings suggest that the response to immunotherapy is associated with tertiary lymphoid structures containing TFH and GC B cells (Cabrita et al. 2020; Helmink et al. 2020; Petitprez et al. 2020).”
BackgroundZeng, Q., Yang, J., Ji, J., Wang, P., Zhang, L., Yan, G., Wu, Y., Chen, Q., Liu, J., Zhang, G., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2061396 · Cited by 54
Zhou, L., Xu, B., Liu, Y., & Wang, Z. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1915574 · Cited by 53
Next-generation antigen-presenting cell immune therapeutics for gliomas
Lee-Chang, C., & Lesniak, M. S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163449 · Cited by 55
“Moreover, B cells and TLS densities increased during treatment only in responding patients (70).”
Regulatory B Cells—Immunopathological and Prognostic Potential in Humans
Veh, J., Ludwig, C., Schrezenmeier, H., & Jahrsdörfer, B. (2024) · Cells · doi:10.3390/cells13040357 · Cited by 58
Wang, Q., Zhong, W., Shen, X., Hao, Z., Wan, M., Yang, X., An, R., Zhu, H., Cai, H., Li, T., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00533-w · Cited by 51
Network Approaches for Dissecting the Immune System
Shi, H., Yan, K., Ding, L., Qian, C., Chi, H., & Yu, J. (2020) · iScience · doi:10.1016/j.isci.2020.101354 · Cited by 51
The neglected brothers come of age: B cells and cancer
Shalapour, S., & Karin, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101479 · Cited by 51
Qin, Y., Peng, F., Ai, L., Mu, S., Li, Y., Yang, C., & Hu, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02004-9 · Cited by 50
Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1–Dependent Myeloid Cells
de Velde, L.-A. V., Allen, E. K., Crawford, J. C., Wilson, T. L., Guy, C. S., Russier, M., Zeitler, L., Bahrami, A., Finkelstein, D., Pelletier, S. W., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0691 · Cited by 46
“The role of B lymphocytes in the antitumor immune response to solid tumors remains poorly understood, with both anti-and protumor roles reported (42 – 44), and no studies to date have systematically investigated the role of B cells in neuroblastoma.”
Metadata
- Authors
- Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., Gopalakrishnan, V., Xi, Y., Zhao, H., Amaria, R. N., Tawbi, H. A., Cogdill, A. P., Liu, W., LeBleu, V. S., Kugeratski, F. G., Patel, S., Davies, M. A., Hwu, P., Lee, J. E., Gershenwald, J. E., Lucci, A., Arora, R., Woodman, S., Keung, E. Z., Gaudreau, P.-O., Reuben, A., Spencer, C. N., Burton, E. M., Haydu, L. E., Lazar, A. J., Zapassodi, R., Hudgens, C. W., Ledesma, D. A., Ong, S., Bailey, M., Warren, S., Rao, D., Krijgsman, O., Rozeman, E. A., Peeper, D., Blank, C. U., Schumacher, T. N., Butterfield, L. H., Zelazowska, M. A., McBride, K. M., Kalluri, R., Allison, J., Petitprez, F., Fridman, W. H., Sautès-Fridman, C., Hacohen, N., Rezvani, K., Sharma, P., Tetzlaff, M. T., Wang, L., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Parker Institute for Cancer Immunotherapy (US)
- Nanostring Technologies (United States) (US)
- The Netherlands Cancer Institute (NL)
- University of Pittsburgh (US)
- Inserm (FR)
- Corresponding author
- Helmink, Beth A.
- Wargo, Jennifer A.
- ORCID
- Helmink, Beth A.
- Reddy, Sangeetha M.
- Gao, Jianjun
- Zhang, Shaojun
- Thakur, Rohit
- Yizhak, Keren
- Sade-Feldman, Moshe
- Blando, Jorge
- Han, Guangchun
- Gopalakrishnan, Vancheswaran
- Xi, Yuanxin
- Zhao, Hao
- Liu, Wenbin
- LeBleu, Valerie S.
- Kugeratski, Fernanda G.
- Patel, Sapna
- Davies, Michael A.
- Hwu, Patrick
- Lee, Jeffrey E.
- Gershenwald, Jeffrey E.
- Lucci, Anthony
- Arora, Reetakshi
- Woodman, Scott
- Keung, Emily Z.
- Gaudreau, Pierre-Olivier
- Reuben, Alexandre
- Spencer, Christine N.
- Burton, Elizabeth M.
- Haydu, Lauren E.
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Rao, Disha
- Krijgsman, Oscar
- Rozeman, Elisa A.
- Peeper, Daniel
- Blank, Christian U.
- Schumacher, Ton N.
- Zelazowska, Monika A.
- McBride, Kevin M.
- Kalluri, Raghu
- Allison, James
- Petitprez, Florent
- Fridman, Wolf Herman
- Hacohen, Nir
- Rezvani, Katayoun
- Sharma, Padmanee
- Wang, Linghua
- Wargo, Jennifer A.
- Venue
- Nature
- Published
- 2020-01-15
- Volume
- 577
- Issue
- 7791
- Pages
- 549-555
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8762581
- OpenAlex
- W2998795792
- Cited by
- 2,731
- References
- 66
- Citations by year
- 2026: 422 · 2025: 422 · 2024: 458 · 2023: 393 · 2022: 433 · 2021: 383 · 2020: 217
- FWCI
- 129.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- AIM at Melanoma
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (W81XWH, CA- 016672)
- University of Texas MD Anderson Cancer Center ((CA016672), T32 CA 009599, P30-CA-016672)
- National Cancer Institute (T32CA009666, R01CA213233, CA213233, R01CA195733, CA195733, P30CA008748, T32CA009599, P30CA016672, P01CA117969)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- B cells, tertiary lymphoid structures, immune checkpoint blockade, cancer immunotherapy response, melanoma, renal cell carcinoma, switched memory B cells, B cell clonal expansion, tumor immune microenvironment, predictive biomarkers, MCP-counter, tumor-infiltrating immune cells
- MeSH terms
- Tertiary Lymphoid Structures, RNA-Seq, B-Lymphocytes, Carcinoma, Renal Cell, Clone Cells, Humans, Immunologic Memory, Immunotherapy, Melanoma, Neoplasm Metastasis, Phenotype, Prognosis, Receptors, Immunologic, Mass Spectrometry, T-Lymphocytes, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Dendritic Cells, Follicular, Single-Cell Analysis, Cell Cycle Checkpoints, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
